BioMarin Pharmaceuticals (BMRN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 30, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BMRN SEC filings page.
BioMarin Pharmaceuticals Inc (BMRN) reported $3.4B in revenue over the twelve months to Jun 30, 2026, up 11.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BioMarin’s growth is producing more cash, but 2025 spending growth compressed margins and reduced reported profit.
In FY2025, operating cash flow rose44.5% while net income fell18.3% , and operating cash flow reached237.3% of net income; cash generation therefore diverged sharply from reported earnings. That happened even as receivables climbed37.5% , so the improvement reflects more than simply reducing money tied up with customers.
Revenue grew
Debt-to-equity was 0.1x, with liabilities at
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of BioMarin Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BioMarin Pharmaceuticals Inc has an operating margin of 12.7%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 59/100, indicating healthy but not exceptional operating efficiency. This is down from 17.0% the prior year.
BioMarin Pharmaceuticals Inc's revenue grew 12.9% year-over-year to $3.2B, a solid pace of expansion. This earns a growth score of 76/100.
BioMarin Pharmaceuticals Inc carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.21, BioMarin Pharmaceuticals Inc holds $5.21 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 92/100.
BioMarin Pharmaceuticals Inc converts 22.5% of revenue into free cash flow ($725.0M). This strong cash generation earns a score of 81/100.
BioMarin Pharmaceuticals Inc's ROE of 5.7% shows moderate profitability relative to equity, earning a score of 46/100. This is down from 7.5% the prior year.
BioMarin Pharmaceuticals Inc scores 5.64, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $11.3B against total liabilities of $1.5B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BioMarin Pharmaceuticals Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, BioMarin Pharmaceuticals Inc generates $2.37 in operating cash flow ($828.0M OCF vs $348.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
BioMarin Pharmaceuticals Inc earns $37.57 in operating income for every $1 of interest expense ($409.5M vs $10.9M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
BioMarin Pharmaceuticals Inc generated $989.7M in revenue in Q2 2026. This represents an increase of 19.9% from the same quarter a year earlier. Against the prior quarter it is up 29.2%.
BioMarin Pharmaceuticals Inc's EBITDA was $208.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 29.4% from the same quarter a year earlier. Against the prior quarter it is up 42.8%.
BioMarin Pharmaceuticals Inc reported $44.8M in net income in Q2 2026. This represents a decrease of 81.4% from the same quarter a year earlier. Against the prior quarter it is down 57.6%.
BioMarin Pharmaceuticals Inc earned $0.23 per diluted share (EPS) in Q2 2026. This represents a decrease of 81.3% from the same quarter a year earlier. Against the prior quarter it is down 57.4%.
Cash & Balance Sheet
BioMarin Pharmaceuticals Inc generated $139.3M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 17.2% from the same quarter a year earlier. Against the prior quarter it is down 30.3%.
BioMarin Pharmaceuticals Inc held $874.0M in cash against $3.5B in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
BioMarin Pharmaceuticals Inc's gross margin was 79.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.0 percentage points.
BioMarin Pharmaceuticals Inc's operating margin was 11.2% in Q2 2026, reflecting core business profitability. This is down 22.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.7 percentage points.
BioMarin Pharmaceuticals Inc's net profit margin was 4.5% in Q2 2026, showing the share of revenue converted to profit. This is down 24.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.3 percentage points.
BioMarin Pharmaceuticals Inc's quarterly ROE was 0.7% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.0 percentage points.
Capital Allocation
BioMarin Pharmaceuticals Inc invested $207.0M in research and development in Q2 2026. This represents an increase of 28.3% from the same quarter a year earlier. Against the prior quarter it is up 15.7%.
BioMarin Pharmaceuticals Inc invested $28.8M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 68.5% from the same quarter a year earlier. Against the prior quarter it is up 37.7%.
Not reported for Q2 2026.
BMRN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $989.7M+19.9% | $766.2M+2.8% | $874.6M+17.0% | $776.1M+4.1% | $825.4M+15.9% | $745.1M+14.8% | $747.3M+15.6% | $745.7M+28.3% |
| Cost of Revenue | $202.8M+35.1% | $195.0M+28.7% | $275.7M+102.5% | $140.1M-25.7% | $150.1M+15.0% | $151.6M+21.1% | $136.1M-1.3% | $188.5M+47.2% |
| Gross Profit | $786.9M+16.5% | $571.2M-3.8% | $598.9M-2.0% | $636.0M+14.1% | $675.3M+16.1% | $593.6M+13.4% | $611.2M+20.2% | $557.3M+22.9% |
| R&D Expenses | $207.0M+28.3% | $178.8M+12.6% | $192.4M+10.9% | $409.5M+121.5% | $161.3M-12.2% | $158.7M-22.6% | $173.5M-15.9% | $184.9M-3.4% |
| SG&A Expenses | $395.5M+70.3% | $258.3M+25.3% | $446.2M+67.4% | $268.4M+5.9% | $232.3M-11.7% | $206.1M-8.8% | $266.6M+2.7% | $253.5M+17.5% |
| Operating Income | $110.9M-59.9% | $129.6M-42.1% | -$44.6M-127.6% | -$46.7M-141.0% | $276.9M+129.9% | $223.9M+153.1% | $161.4M+491.7% | $113.9M+273.1% |
| EBITDA | $208.6M-29.4% | $146.1M-40.6% | -$24.2M-113.1% | -$28.2M-121.2% | $295.4M+101.1% | $246.0M+112.4% | $185.0M+241.7% | $132.9M+136.4% |
| Interest Expense | $63.3M+2262.6% | $15.0M+422.5% | $2.8M+7.8% | $2.6M-13.1% | $2.7M-25.0% | $2.9M-19.3% | $2.6M-57.7% | $3.0M-21.5% |
| Income Tax | $16.6M-71.0% | $35.7M-31.9% | $19.4M-56.6% | $4.4M-84.4% | $57.3M+129.7% | $52.4M+210.4% | $44.7Mn/m | $28.4M+2096.8% |
| Net Income | $44.8M-81.4% | $105.5M-43.2% | -$46.6M-137.3% | -$30.7M-129.0% | $240.5M+124.4% | $185.7M+109.4% | $124.9M+513.2% | $106.1M+162.7% |
| EPS (Basic) | $0.23-81.6% | $0.55-43.3% | -$0.24-136.4% | -$0.16-128.6% | $1.25+123.2% | $0.97+106.4% | $0.66+500.0% | $0.56+166.7% |
| EPS (Diluted) | $0.23-81.3% | $0.54-43.2% | -$0.24-136.9% | -$0.16-129.1% | $1.23+123.6% | $0.95+106.5% | $0.65+550.0% | $0.55+161.9% |
| Diluted Shares (Avg) | 194M-1.3% | 198M+0.6% | N/A | 192M-2.6% | 197M-1.7% | 196M-1.4% | N/A | 197M+3.1% |
BMRN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.7B+57.2% | $8.6B+20.2% | $7.6B+8.7% | $7.6B+11.1% | $7.5B+5.5% | $7.1B+4.0% | $7.0B+2.2% | $6.9B+1.4% |
| Current Assets | $4.0B+4.4% | $4.6B+32.8% | $4.0B+22.3% | $3.9B+26.1% | $3.8B+16.7% | $3.5B+16.2% | $3.2B+9.3% | $3.1B+3.4% |
| Cash & Equivalents | $874.0M-28.0% | $2.2B+111.9% | $1.3B+39.1% | $1.3B+85.1% | $1.2B+24.9% | $1.0B+40.4% | $942.8M+24.9% | $675.4M-14.0% |
| Short-Term Investments | $0-100.0% | $0-100.0% | $248.9M+27.7% | $227.7M-10.7% | $218.3M-13.4% | $223.5M-25.4% | $194.9M-38.9% | $255.0M-25.1% |
| Inventory | $1.8B+33.0% | $1.3B-0.1% | $1.3B+5.4% | $1.4B+17.2% | $1.3B+13.2% | $1.3B+12.0% | $1.2B+11.3% | $1.2B+14.3% |
| Accounts Receivable | $1.1B+24.0% | $903.9M+22.3% | $908.2M+37.5% | $790.3M+1.6% | $855.9M+23.8% | $739.2M+16.0% | $660.5M+4.2% | $777.5M+35.8% |
| Long-Term Investments | $0-100.0% | $0-100.0% | $492.2M-5.6% | $512.9M-8.7% | $508.6M-8.7% | $506.7M-18.3% | $521.2M-14.7% | $562.0M+2.6% |
| Goodwill | $655.7M+234.2% | $196.2M0.0% | $196.2M0.0% | $196.2M0.0% | $196.2M0.0% | $196.2M0.0% | $196.2M0.0% | $196.2M0.0% |
| Total Liabilities | $5.4B+277.9% | $2.4B+75.8% | $1.5B+13.2% | $1.6B+8.4% | $1.4B-19.7% | $1.4B-24.8% | $1.3B-29.6% | $1.4B-22.8% |
| Current Liabilities | $1.7B+143.2% | $793.2M+26.3% | $759.0M+25.0% | $798.4M+11.6% | $684.2M-35.9% | $628.2M-42.3% | $607.0M-48.4% | $715.7M-38.5% |
| Non-Current Liabilities | $3.7B+401.7% | $1.6B+118.6% | $748.0M+3.3% | $759.7M+5.2% | $745.0M+4.4% | $725.3M+2.0% | $724.0M+1.5% | $722.1M+3.5% |
| Long-Term Debt | $3.5B+491.8% | $1.4B+140.1% | $597.2M+0.3% | $596.7M+0.3% | $596.2M+0.3% | $595.6M+0.3% | $595.1M+0.3% | $594.6M+0.3% |
| Total Equity | $6.3B+4.9% | $6.2B+7.2% | $6.1B+7.6% | $6.1B+11.9% | $6.0B+14.0% | $5.8B+14.2% | $5.7B+14.3% | $5.4B+10.5% |
| Retained Earnings | $304.5M+31.5% | $259.7Mn/m | $154.2Mn/m | $200.8Mn/m | $231.5Mn/m | -$9.0Mn/m | -$194.7Mn/m | -$319.6Mn/m |
BMRN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $168.1M-9.3% | $220.7M+26.5% | $99.6M-46.3% | $368.7M+66.5% | $185.3M+56.0% | $174.4M+271.3% | $185.6M+575.4% | $221.5M+63.3% |
| Depreciation & Amortization | $97.6M+426.0% | $16.4M-25.6% | $20.4M-13.4% | $18.5M-2.7% | $18.6M-29.9% | $22.1M-19.3% | $23.6M-12.1% | $19.0M-26.0% |
| Stock-Based Compensation | $75.7M+59.3% | $43.5M+15.3% | N/A | $49.3M+13.3% | $47.5M-0.8% | $37.7M-35.3% | N/A | $43.5M-10.1% |
| Capital Expenditures | $28.8M+68.5% | $20.9M+24.8% | $40.7M+108.5% | $28.4M+54.1% | $17.1M-19.8% | $16.8M-35.8% | $19.5M-32.5% | $18.5M-15.1% |
| Free Cash Flow | $139.3M-17.2% | $199.7M+26.7% | $58.9M-64.5% | $340.2M+67.6% | $168.2M+72.6% | $157.6M+655.4% | $166.1Mn/m | $203.0M+78.2% |
| Investing Cash Flow | -$5.1Bn/m | $725.5Mn/m | -$42.4M-155.6% | -$331.0Mn/m | -$12.6M-113.9% | -$28.2Mn/m | $76.4Mn/m | -$16.2Mn/m |
| Financing Cash Flow | $2.7Bn/m | $813.2Mn/m | $3.2M+10.4% | -$2.2Mn/m | -$4.6M-136.5% | -$38.8Mn/m | $2.9M-73.6% | -$499.1Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BMRN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.5%-2.3pp | 74.6%-5.1pp | 68.5%-13.3pp | 82.0%+7.2pp | 81.8%+0.1pp | 79.7%-1.1pp | 81.8%+3.1pp | 74.7%-3.2pp |
| Operating Margin | 11.2%-22.3pp | 16.9%-13.1pp | -5.1%-26.7pp | -6.0%-21.3pp | 33.6%+16.6pp | 30.0%+16.4pp | 21.6%+17.4pp | 15.3%+10.0pp |
| Net Margin | 4.5%-24.6pp | 13.8%-11.2pp | -5.3%-22.0pp | -4.0%-18.2pp | 29.1%+14.1pp | 24.9%+11.3pp | 16.7%+13.6pp | 14.2%+7.3pp |
| Return on Equity | 0.7%-3.3pp | 1.7%-1.5pp | -0.8%-3.0pp | -0.5%-2.5pp | 4.0%+2.0pp | 3.2%+1.5pp | 2.2%+1.8pp | 2.0%+1.1pp |
| Return on Assets | 0.4%-2.9pp | 1.2%-1.4pp | -0.6%-2.4pp | -0.4%-1.9pp | 3.2%+1.7pp | 2.6%+1.3pp | 1.8%+1.5pp | 1.6%+0.9pp |
| Current Ratio | 2.39-3.2x | 5.81+0.3x | 5.21-0.1x | 4.83+0.6x | 5.56+2.5x | 5.52+2.8x | 5.33+2.8x | 4.27+1.7x |
| Debt-to-Equity | 0.56+0.5x | 0.23+0.1x | 0.100.0x | 0.100.0x | 0.100.0x | 0.100.0x | 0.110.0x | 0.110.0x |
| Liabilities-to-Equity | 0.85+0.6x | 0.38+0.1x | 0.250.0x | 0.260.0x | 0.24-0.1x | 0.23-0.1x | 0.24-0.1x | 0.27-0.1x |
| Asset Turnover | 0.080.0x | 0.090.0x | 0.120.0x | 0.100.0x | 0.110.0x | 0.100.0x | 0.110.0x | 0.110.0x |
| FCF Margin | 14.1%-6.3pp | 26.1%+4.9pp | 6.7%-15.5pp | 43.8%+16.6pp | 20.4%+6.7pp | 21.1%+17.9pp | 22.2%+22.4pp | 27.2%+7.6pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceuticals Inc BMRN | FY2025 | $3.2B | $348.9M | 10.8% | $11.3B | 75/100 |
| Ionis Pharmaceuticals, Inc. IONS | FY2025 | $943.7M | -$381.4M | -40.4% | $7.2B | 68/100 |
| BridgeBio Pharma, Inc. BBIO | FY2025 | $502.1M | -$724.9M | N/A | $14.7B | 59/100 |
| Exelixis Inc EXEL | FY2025 | $2.3B | $782.6M | 33.7% | $17.2B | 80/100 |
| Ascendis Pharma A/S ASND | FY2025 | $845.1M | -$267.6M | -31.7% | $16.5B | 75/100 |
| Summit Therapeutics Inc. SMMT | FY2025 | N/A | -$1.1B | N/A | $12.8B | — |
Where BioMarin Pharmaceuticals Inc Ranks
Frequently Asked Questions
What is BioMarin Pharmaceuticals Inc's annual revenue?
BioMarin Pharmaceuticals Inc (BMRN) reported $3.2B in total revenue for fiscal year 2025. This represents a 12.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BioMarin Pharmaceuticals Inc's revenue growing?
BioMarin Pharmaceuticals Inc (BMRN) revenue grew by 12.9% year-over-year, from $2.9B to $3.2B in fiscal year 2025.
Is BioMarin Pharmaceuticals Inc profitable?
Yes, BioMarin Pharmaceuticals Inc (BMRN) reported a net income of $73.0M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $348.9M, with a net profit margin of 10.8%.
What is BioMarin Pharmaceuticals Inc's EBITDA?
BioMarin Pharmaceuticals Inc (BMRN) had EBITDA of $489.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does BioMarin Pharmaceuticals Inc have?
As of fiscal year 2025, BioMarin Pharmaceuticals Inc (BMRN) had $1.3B in cash and equivalents against $597.2M in long-term debt.
What is BioMarin Pharmaceuticals Inc's gross margin?
BioMarin Pharmaceuticals Inc (BMRN) had a gross margin of 77.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is BioMarin Pharmaceuticals Inc's operating margin?
BioMarin Pharmaceuticals Inc (BMRN) had an operating margin of 12.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is BioMarin Pharmaceuticals Inc's net profit margin?
BioMarin Pharmaceuticals Inc (BMRN) had a net profit margin of 10.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is BioMarin Pharmaceuticals Inc's return on equity (ROE)?
BioMarin Pharmaceuticals Inc (BMRN) has a return on equity of 5.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioMarin Pharmaceuticals Inc's free cash flow?
BioMarin Pharmaceuticals Inc (BMRN) generated $725.0M in free cash flow during fiscal year 2025. This represents a 48.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioMarin Pharmaceuticals Inc's operating cash flow?
BioMarin Pharmaceuticals Inc (BMRN) generated $828.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are BioMarin Pharmaceuticals Inc's total assets?
BioMarin Pharmaceuticals Inc (BMRN) had $7.6B in total assets as of fiscal year 2025, including both current and long-term assets.
What are BioMarin Pharmaceuticals Inc's capital expenditures?
BioMarin Pharmaceuticals Inc (BMRN) invested $103.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BioMarin Pharmaceuticals Inc spend on research and development?
BioMarin Pharmaceuticals Inc (BMRN) invested $921.9M in research and development during fiscal year 2025.
What is BioMarin Pharmaceuticals Inc's current ratio?
BioMarin Pharmaceuticals Inc (BMRN) had a current ratio of 5.21 as of fiscal year 2025, which is generally considered healthy.
What is BioMarin Pharmaceuticals Inc's debt-to-equity ratio?
BioMarin Pharmaceuticals Inc (BMRN) had a debt-to-equity ratio of 0.10 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is BioMarin Pharmaceuticals Inc's liabilities-to-equity ratio?
BioMarin Pharmaceuticals Inc (BMRN) had a liabilities-to-equity ratio of 0.25 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is BioMarin Pharmaceuticals Inc's return on assets (ROA)?
BioMarin Pharmaceuticals Inc (BMRN) had a return on assets of 4.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BioMarin Pharmaceuticals Inc's P/E ratio?
BioMarin Pharmaceuticals Inc (BMRN) trades at 155x earnings, its market capitalization divided by $73.0M net income, trailing 12 months to June 30, 2026. The market capitalization is $11.3B as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioMarin Pharmaceuticals Inc's price-to-sales ratio?
BioMarin Pharmaceuticals Inc (BMRN) trades at 3.3x sales, its market capitalization divided by $3.4B revenue, trailing 12 months to June 30, 2026. The market capitalization is $11.3B as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioMarin Pharmaceuticals Inc's Altman Z-Score?
BioMarin Pharmaceuticals Inc (BMRN) has an Altman Z-Score of 5.64, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BioMarin Pharmaceuticals Inc's Piotroski F-Score?
BioMarin Pharmaceuticals Inc (BMRN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioMarin Pharmaceuticals Inc's earnings high quality?
BioMarin Pharmaceuticals Inc (BMRN) has an earnings quality ratio of 2.37x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BioMarin Pharmaceuticals Inc cover its interest payments?
BioMarin Pharmaceuticals Inc (BMRN) has an interest coverage ratio of 37.57x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is BioMarin Pharmaceuticals Inc?
BioMarin Pharmaceuticals Inc (BMRN) scores 75 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.